Toxicity studies
Dive into injection site reaction assessment
Immunotoxicity at the injection site
Decoding Injection Site Reactogenicity & Immunotoxicity: A Novel Approach Integrating Human Skin Models with Secretome & Pathway Analytics (SOT 2024)
Emeline Pagès1, Mathias Peries1, Emilie Braun1, Manon Scholaert1, Kimbria Blake3, Alexandra Ochando3 Nicolas Gaudenzio1,2 – 1Genoskin SAS, Toulouse, France – 2Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France – 3Genoskin Inc, Salem MA, USA
Automated prediction of drug reactogenicity at the site of injection, by combining natural human skin & computational inference of biological pathways (EUROTOX 2023)
Emeline Pagès1, Mathias Peries1, Emilie Braun1, Manon Scholaert1,2, Katarzyna Polak1, Nicolas Gaudenzio1,2 – 1Genoskin SAS, Toulouse, France – 2Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France – 3Genoskin Inc, Salem MA, USA
Mitigation of injection site reaction (customer poster)
Mitigation of Injection site reactions after subcutaneous administration of Dalcinonacog Alfa (DalcA) in Hemophilia B using preclinical models.
Natacha Le Moan1, Lauren Kelly1, Eric Merle2, Pascal Descargues2, Nicolas Gaudenzio2, Hugo Gagnon3, Anju Chatterji1, Grant E. Blouze1 – 1Catalyst Biosciences, South San Francisco, CA, USA – 2Genoskin, Inc., 4 Technology Way, Salem, MA, 01970, USA – 3Phenoswitch Biosciences, 975 Rue Léon-Trépanier, Sherbrooke, QC J1G 5J6, Canada.
DOWNLOAD POSTER
